Literature DB >> 17027944

Mechanisms of the in vivo inhibition of calcification of bioprosthetic porcine aortic valve cusps and aortic wall with triglycidylamine/mercapto bisphosphonate.

H Scott Rapoport1, Jeanne M Connolly, James Fulmer, Ning Dai, Brandon H Murti, Robert C Gorman, Joseph H Gorman, Ivan Alferiev, Robert J Levy.   

Abstract

Heart valve replacements fabricated from glutaraldehyde (Glut)-crosslinked heterograft materials, porcine aortic valves or bovine pericardium, have been widely used in cardiac surgery to treat heart valve disease. However, these bioprosthetic heart valves often fail in long-term clinical implants due to pathologic calcification of the bioprosthetic leaflets, and for stentless porcine aortic valve bioprostheses, bioprosthetic aortic wall calcification also typically occurs. Previous use of the epoxide-based crosslinker, triglycidyl amine (TGA), on cardiac bioprosthetic valve materials demonstrated superior biocompatibility, mechanics, and calcification resistance for porcine aortic valve cusps (but not porcine aortic wall) and bovine pericardium, vs. Glut-prepared controls. However, TGA preparation did not completely prevent long-term calcification of cusps or pericardium. Herein we report further mechanistic investigations of an added therapeutic component to this system, 2-mercaptoethylidene-1,1-bisphosphonic acid (MABP), a custom synthesized thiol bisphosphonate, which has previously been shown in a preliminary report to prevent bioprosthetic heterograft biomaterial calcification when used in combination with initial TGA crosslinking for 7 days. In the present studies, we have further investigated the effectiveness of MABP in experiments that examined: (1) The use of MABP after optimal TGA crosslinking, in order to avoid any competitive interference of MABP-reactions with TGA during crosslinking; (2) Furthermore, recognizing the importance of alkaline phosphatase (ALP) in the formation of dystrophic calcific nodules, we have investigated the hypothesis that the mechanism by which MABP primarily functions is through the reduction of ALP activity. Results from cell-free model systems, cell culture studies, and rat subcutaneous implants, show that materials functionalized with MABP after TGA crosslinking have reduced ALP activity, and in vivo have no significant calcification in long-term implant studies. It is concluded that bioprosthetic heart valves prepared in this fashion are compelling alternatives for Glut-prepared bioprostheses.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17027944      PMCID: PMC1829417          DOI: 10.1016/j.biomaterials.2006.09.029

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  26 in total

1.  Influence of glutaraldehyde fixation on the detection of SLA-I and II antigens and calcification tendency in porcine cardiac tissue.

Authors:  M Mirzaie; T Meyer; A Saalmüller; H Dalichau
Journal:  Scand Cardiovasc J       Date:  2000-12       Impact factor: 1.589

2.  Cell-free xenogenic vascular grafts fixed with glutaraldehyde or genipin: in vitro and in vivo studies.

Authors:  Yen Chang; Cheng-Kuo Hsu; Hao-Ji Wei; Sung-Ching Chen; Huang-Chien Liang; Po-Hong Lai; Hsing-Wen Sung
Journal:  J Biotechnol       Date:  2005-08-19       Impact factor: 3.307

3.  A modification of Movat's pentachrome stain.

Authors:  H K Russell
Journal:  Arch Pathol       Date:  1972-08

4.  Bisphosphonate derivatized polyurethanes resist calcification.

Authors:  I Alferiev; N Vyavahare; C Song; J Connolly; J T Hinson; Z Lu; S Tallapragada; R Bianco; R Levy
Journal:  Biomaterials       Date:  2001-10       Impact factor: 12.479

5.  Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis.

Authors:  Bo Jian; Navneet Narula; Quan-yi Li; Emile R Mohler; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2003-02       Impact factor: 4.330

6.  Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups.

Authors:  C L Webb; J J Benedict; F J Schoen; J A Linden; R J Levy
Journal:  Ann Thorac Surg       Date:  1988-09       Impact factor: 4.330

7.  Alkaline phosphatase activity of glutaraldehyde-treated bovine pericardium used in bioprosthetic cardiac valves.

Authors:  A R Maranto; F J Schoen
Journal:  Circ Res       Date:  1988-10       Impact factor: 17.367

8.  Nucleotide and amino acid sequences of human intestinal alkaline phosphatase: close homology to placental alkaline phosphatase.

Authors:  P S Henthorn; M Raducha; Y H Edwards; M J Weiss; C Slaughter; M A Lafferty; H Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

9.  Phosphatase enzyme activity is retained in glutaraldehyde treated bioprosthetic heart valves.

Authors:  A R Maranto; F J Schoen
Journal:  ASAIO Trans       Date:  1988 Jul-Sep

10.  Covalent binding of aminopropanehydroxydiphosphonate to glutaraldehyde residues in pericardial bioprosthetic tissue: stability and calcification inhibition studies.

Authors:  C L Webb; F J Schoen; R J Levy
Journal:  Exp Mol Pathol       Date:  1989-06       Impact factor: 3.362

View more
  9 in total

Review 1.  The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.

Authors:  Sammy Elmariah; Emile R Mohler
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

2.  Is autologous or heterologous pericardium better for valvuloplasty? A comparative study of calcification propensity.

Authors:  Wen-Jian Jiang; Yong-Chao Cui; Jin-Hua Li; Xiu-Hui Zhang; Huan-Huan Ding; Yong-Qiang Lai; Hong-Jia Zhang
Journal:  Tex Heart Inst J       Date:  2015-06-01

3.  Exogenous hyaluronic acid and chondroitin sulfate crosslinking treatment for increasing the amount and stability of glycosaminoglycans in bioprosthetic heart valves.

Authors:  Yang Lei; Qinggong Ning; Yuyang Tang; Yunbing Wang
Journal:  J Mater Sci Mater Med       Date:  2019-03-06       Impact factor: 3.896

4.  Triglycidyl amine crosslinking combined with ethanol inhibits bioprosthetic heart valve calcification.

Authors:  Jeanne M Connolly; Marina A Bakay; Ivan S Alferiev; Robert C Gorman; Joseph H Gorman; Howard S Kruth; Paul E Ashworth; Jaishankar K Kutty; Frederick J Schoen; Richard W Bianco; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2011-09       Impact factor: 4.330

5.  Effects of cyclic flexural fatigue on porcine bioprosthetic heart valve heterograft biomaterials.

Authors:  Ali Mirnajafi; Brett Zubiate; Michael S Sacks
Journal:  J Biomed Mater Res A       Date:  2010-07       Impact factor: 4.396

6.  In vivo biomechanical assessment of triglycidylamine crosslinked pericardium.

Authors:  Michael S Sacks; Hirotsugu Hamamoto; Jeanne M Connolly; Robert C Gorman; Joseph H Gorman; Robert J Levy
Journal:  Biomaterials       Date:  2007-09-05       Impact factor: 12.479

7.  Model studies of advanced glycation end product modification of heterograft biomaterials: The effects of in vitro glucose, glyoxal, and serum albumin on collagen structure and mechanical properties.

Authors:  Christopher A Rock; Samuel Keeney; Andrey Zakharchenko; Hajime Takano; David A Spiegel; Abba M Krieger; Giovanni Ferrari; Robert J Levy
Journal:  Acta Biomater       Date:  2021-01-11       Impact factor: 8.947

Review 8.  Aortic Valve Stenosis and Mitochondrial Dysfunctions: Clinical and Molecular Perspectives.

Authors:  Gaia Pedriali; Giampaolo Morciano; Simone Patergnani; Paolo Cimaglia; Cristina Morelli; Elisa Mikus; Roberto Ferrari; Vincenzo Gasbarro; Carlotta Giorgi; Mariusz R Wieckowski; Paolo Pinton
Journal:  Int J Mol Sci       Date:  2020-07-11       Impact factor: 5.923

9.  Immobilized Bisphosphonates as Potential Inhibitors of Bioprosthetic Calcification: Effects on Various Xenogeneic Cardiovascular Tissues.

Authors:  Irina Y Zhuravleva; Anna A Dokuchaeva; Elena V Karpova; Tatyana P Timchenko; Anatoly T Titov; Svetlana S Shatskaya; Yuliya F Polienko
Journal:  Biomedicines       Date:  2021-12-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.